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REVIEW AND COMPARISON OF DIFFERENT NATIONAL GUIDELINES ON THE
IMPLEMENTATION OF NETWORK META-ANALYSIS
Hawkins N1, Laws AJ2, Kendall RM2
1Oxford Outcomes, Oxford, UK, 2Oxford Outcomes, Vancouver, BC, Canada
OBJECTIVES: For an evaluation of a treatment to be truly useful, it should be com-
pared to the other treatments that may be used in the patient group under consid-
eration. Randomised controlled trials are a key source of evidence for these com-
parisons. The techniques of indirect comparisons and network meta-analysis
allow the complete network of trial evidence to be evaluated in order to obtain
estimates of comparative efficacy. These techniques may be the only source of
estimates of comparative effectiveness if trials directly comparing the treatments
of interest have not been conducted andmay provide useful additional evidence if
both direct and indirect comparisons exist. METHODS: We examined both pub-
lished and draft guidelines from reimbursement and health technology appraisal
bodies, and considered their recommendations using appropriatemethodology for
the conduct of indirect comparisons and the assessments of their validity.
RESULTS: The following countries were studied; Australia, Canada, France, Ger-
many, Korea, Sweden, and USA, with particular emphasis on the differences and
similarities in these guidelines with each other, and with the guidelines estab-
lished by the Cochrane collaboration. CONCLUSIONS: Finally, we present an ex-
ample analysis demonstrating how the various requirements could bemet in prac-
tice.
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GLOBAL EVIDENCE GENERATION - CHALLENGES FOR THE PHARMA INDUSTRY
Mukku S
Double Helix Consulting Group, London, UK
Health technology assessments around the world are changing at a pace that it is
becoming extremely difficult for the pharmaceutical companies to keep up to the
demands of health authorities around the world. Market access, commercial and
more specifically clinical development teams are facing a mamoth task of devel-
oping and generating clinical data in a form that will satisfy the increasing expec-
tations of health care systems around the world. OBJECTIVES: This research paper
analysis the current trends in data expectations from key markets around the
world. This specific objective was to develop a matrix that will identify the differ-
ences and commonalities in clinical data expectations in selected key markets of
US, France, Germany, UK, The Netherlands, Spain, Italy, Poland, China, Australia,
Turkey, India, Brazil and Mexico. METHODS: A combination of ndepth secondary
research followed by interviews with key stakeholders in eachmarket was used to
achieve the objectives of the project. Clinical experts who are involved in clinical
trial design in key research centres, payers at the national and regional level and
executives from pharmaceutical industry were interviewed. RESULTS: It was con-
cluded that there is huge variance in data expectations in the selectedmarkets and
for this reason countries could be placed in different buckets. For instance, some
countries focus on economic assessment (UK, Australia) while other focus on well
designed RCTs against relevant comparator (Germany, France). The 2011 introduc-
tion of AMNOG has resulted in deadlock between the manufacturers and the GBA
(Joint federal committee) in Germany on the choice of comparator. Similarly the
new clinical guidelines that are being introduced in China require data with local/
Chinese population. The French Transparency (TC) commission is not considering
drugs as valuable (AMSR scoring) if they are not supported with a well designed
comparator study. The paper elaborates on such global challenges.
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INVESTMENT AND DISINVESTMENT OF HEALTH TECHNOLOGIES: THE NEED
FOR TWO COST-EFFECTIVENESS THRESHOLDS
Paulden M
University of Toronto, Toronto, ON, Canada
OBJECTIVES: The concept of a cost-effectiveness “threshold” has been adopted
either explicitly or implicitly by health care decision makers in numerous jurisdic-
tions. This paper demonstrates that, under very weak assumptions – applicable to
all realworld health systems – decision makers ought to instead adopt two cost-
effectiveness thresholds.METHODS: A simple model of a hypothetical health care
system is used to demonstrate the appropriate threshold(s) under various assump-
tions concerning: 1) the size of the health care budget; 2) the extent to which
technology, productivity and/or input prices change over time; 3) whether the
amount of information available to decision makers changes over time; and 4) the
fixity of the set of adopted health care technologies in the short term. RESULTS:
The assumptions whichmust hold for two thresholds to be appropriate are that: 1)
there is some fixity in the set of adopted health care technologies in the short term,
and 2) either 1) technology, productivity and/or input prices change over time, or 2)
the information available to decision makers changes over time, or both. Where
these assumptions hold, one threshold ought to be used when appraising technol-
ogies with positive incremental costs (investment decisions), while a different
threshold should be usedwhen appraising technologies with negative incremental
costs (disinvestment decisions). This is true regardless of the marginality of the
technologies under consideration. CONCLUSIONS: This finding has profound im-
plications for the practice of cost-effectiveness analysis, for ongoing and future
empirical research into the nature of the threshold, and for health care policy
making. It gives a theoretical underpinning to observations that the ICERs of tech-
nologies disinvested at themargin differ from those of technologies adopted at the
margin. It also has implications for the interpretation of ICERs, for the appropriate
calculation of net benefit, and for the conduct of value of information analysis.
DISEASE-SPECIFIC STUDIES
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies
PMS1
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF DULOXETINE PATIENTS
WITH CHRONIC LOWER BACK PAIN OR OSTEOARTHRITIS IN 2011
Able SL1, Preston H2, Victor H2
1Eli Lilly and Company, Inc., Indianapolis, IN, USA, 2IMS Health Consulting Group, Plymouth
Meeting, PA, USA
OBJECTIVES: Identify and compare demographic and clinical characteristics of
patients diagnosed with osteoarthritis (OA) or chronic lower back pain (CLBP) who
initiated treatment on duloxetine after FDA approval of its use for management of
chronic musculoskeletal pain late in 2010. METHODS: Commercial patients 18-64
years of age who initiated duloxetine treatment between January 1, 2011 and July
30, 2011 were identified in the IMS Longitudinal Prescription and Medical Claims
Database. The index event was defined as the first duloxetine prescription fill with
no duloxetine pill-coverage for 90 days prior. Patients were assigned to disease-
category cohorts on the basis of ICD-9 codes on medical claims dated within
-180/7 days of the index event. 2-tests were used to compare differences across
study cohorts. Additional cohorts based on other FDA approved duloxetine indica-
tions and for the same time period a year prior to the primary study period were
constructed for comparison. RESULTS: A total of 422,911 duloxetine initiators with
1 of duloxetine’s six approved indications were identified in the IMS database, of
which 80,637 had either CLBP (42,280) or OA (38,357) as the only diagnosed condi-
tion from among the six. OA patients were older than CLBP patients (60.6 vs. 52.1
years; p0.001). An almost equal proportion of OA and CLBP patients (47%) were
treated by primary care physicians. CLBP patients were more likely prescribed an
anticonvulsant (52.7% vs 37.3%; p0.001) or an opioid (93.5% vs. 84.1%; p.001) than
were OA patients. OA patients weremore likely to have been previously diagnosed
with a non-CLBP related musculoskeletal pain condition. OA patients were more
likely to initiate duloxetine treatment at sub-therapeutic (40 mg/day) dosing lev-
els than CLBP patients (32.1% vs. 26.8%; p0.001). Results for 2011 were little
changed from 2010 results. CONCLUSIONS: Overall, patient profiles among dulox-
etine initiatorswith CLBP displayedmodest differentiation relative to patientswith
OA in 2011.
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THE EFFICACY OF DULOXETINE, NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS, AND OPIOIDS IN OSTEOARTHRITIS: A META-ANALYSIS
Myers JA1, Wielage RC1, Han B2, Price K2, Gahn JC1, Paget MA3, Happich M4
1Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Eli Lilly and Company, Inc., Indianapolis,
IN, USA, 3Lilly France S.A., Suresnes Cedex, France, 4Eli Lilly and Company, Inc., Bad Homburg,
Hessia, Germany
OBJECTIVES: Comparative evidence evaluating the efficacy of oral osteoarthritis
treatments has frequently included short-term trials. Meta-analyses of longer-
term trials are needed. This meta-analysis of trials 12 weeks or longer was con-
ducted to assess the efficacy of duloxetine vs. other oral treatments recommended
after the use of acetaminophen for osteoarthritis, including non-steroidal anti-
inflammatory drugs (NSAIDs) and opioids. METHODS: Search strategy: A system-
atic literature review was performed in PUBMED, EMBASE, MedLine In-Process,
Cochrane Library, and ClinicalTrials.gov up to September 2011. Randomized con-
trolled trials (RCTs) of duloxetine and all oral NSAIDs and opioids were included if
the duration of treatment was twelve weeks or longer, the Western Ontario and
McMaster Universities Index (WOMAC) total score was available, and they were
published in English. Data collection and analysis: The WOMAC baseline and
change from baseline total scores were collected and standardized. Twelve addi-
tional study characteristics were collected and study quality was assessed. A fre-
quentist meta-analysis and indirect comparison were performed using the DerSi-
monian-Laird and Bucher methods. Bayesian analyses with and without study-
level covariates were performed using noninformative priors. RESULTS: A search
of the literature identified 24 studies which met inclusion criteria. The frequentist
analysis and the Bayesian analysis without covariates found no statistically signif-
icant difference between the efficacy of duloxetine and the other treatments.Meta-
regression suggested baseline scores explain much of the variance in change from
baseline scores. The results, however, adjusted for study-level covariates led to the
same conclusion. CONCLUSIONS: This analysis suggests that the efficacy of dulox-
etine in osteoarthritis, as measured by the WOMAC total score at 12 weeks or
longer, is similar to competitor drugs.
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COMPARATIVE EFFECTIVENESS ANALYSIS USING “REAL-WORLD” PATIENT
DATABASE TO EVALUATE THE FRACTURES RATES COMPARING ANNUAL
ZOLEDRONIC ACID INFUSION WITH ORAL BISPHOSPHONATES
Lian J1, Song X2, Varker H2, Cao Z2, Recknor C3
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Thomson Reuters, Cambridge,
MA, USA, 3United Osteoporosis Centers, Gainesville, GA, USA
OBJECTIVES: This study evaluated clinical fracture rates before and after two years
of zoledronic acid infusion (ZOL) or oral bisphosphonate (OBP) initiation using a
large national claims data set. METHODS: Patients 45 years with at least one
claim of ZOL or OBP were extracted from Thomson Reuters MarketScan® Data-
bases January 1, 2006-October 31, 2010. Index date was the date of the first ZOL or
OBP claim. Each patient had 1 diagnosis of osteoporosis prior to index date. All
patients had at least two-year continuous enrollment prior to (pre-period) and
two-year continuous enrollment post (follow-up period) index date. Patients with
any ZOL use during the study period were excluded from the OBP cohort. Differ-
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ence-in-difference method was used to estimate changes in fracture rates two
years before and after ZOL or OBP initiation. Generalized estimating equationmod-
els were used to test the hypothesis of differential changes in fracture rates be-
tween ZOL and OBP users, controlling for age, gender, treatment (ZOL vs. OBP), and
time (pre-period vs. follow-up period). RESULTS: A total of 3,102 ZOL and 36,961
OBP users met the study criteria. Over the two-year follow-up, ZOL users experi-
enced a significant reduction in fracture rates compared to the two-year prior to
ZOL (13.4% vs. 11.2%; p0.008) while fracture rates significantly increased for OBP
users (9.0% vs. 9.5%; p0.019). Multivariate regression estimated that the probabil-
ity of experiencing any fracture decreased by 1.97% between pre- and follow up
period for ZOL users (p0.004), increased by 0.46% for OBP users (p0.001), and the
difference-in-difference effect was 2.43%, suggesting that ZOL users experienced a
significant decrease in fracture rates relative to OBP users (p0.001).
CONCLUSIONS: This is the first comparative analysis evaluating fracture rates two
years before and two years after the initiation of ZOL and OBP. Use of ZOL signifi-
cantly reduced fracture rates, compared with the use of OBP.
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COMPARATIVE ANALYSIS BETWEEN COSTS AND CLINICAL RESPONSE OF
BIOLOGIC DRUGS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA)
Cantanheda CRDO, Romão VA, Amino JG, Dias QCP, Simas HS, Bacchiega AB, Azevedo V,
Assis E, Teich VT
Unimed-Rio Cooperativa de Trabalho Médico, Rio de Janeiro, Rio de Janeiro, Brazil
OBJECTIVES: To evaluate costs and clinical response of different treatments with
biologic drugs for rheumatoid arthritis. METHODS: The study was designed as a
prospective cohort. A sample of 15 patients was selected for analysis. Selection
criteria: patients with RA with moderate to severe disease activity, failure to treat-
ment with DMARDS and no previous use of anti-TNF drugs. The following param-
eters were considered in the calculation of direct costs: average doses, treatment
duration, number of doses received and cost per milligram (mg) of each drug. The
clinical outcome evaluated was DAS 28 at day zero and at 160 days. The criteria
considered for low activity of disease was DAS 28 3.2 and for remission DAS 28
2.6. RESULTS: Among the 15 patients included, the average age was 45 years, 33%
were men, with average BMI of 25.81kg/m2, 73% with disease duration above 5
years, and average duration of treatmentwithDMARDs of 2.27 years. Among these,
3 patients were treated with Adalimumab (average dose: 40mg; R$75.13/mg; 6 dos-
es); 3 with Etanercept (average dose: 50mg; R$28.28/mg; 15 doses) and 9 with Inf-
liximab (average dose: 201mg; R$30.77/mg; 4 infusions). The average follow-up
time was 16 weeks. Adalimumab resulted in an average cost of R$18031.41 with a
63% reduction in DAS 28 (2.03), presenting remission criteria. The average cost with
Etanercept was R$21,209.55 with a 3% reduction in DAS 28 (5.31). Infliximab re-
sulted in an average cost of R$ 24,766.11 with a reduction of 26% in DAS 28 (3.23)
presenting criteria for low activity of disease. CONCLUSIONS: The first line treat-
ment of patients withmoderate to severe RAwith Adalimumab presented the best
clinical response in 160 days, achieving criteria for disease remission at the lowest
treatment cost. The treatment with Etanercept resulted in the worst relation be-
tween cost and clinical response.
PMS5
DATA VISUALIZATION OF TREATMENT PATTERNS OF MEDICARE PSORIATIC
ARTHRITIS PATIENTS WHO INITIATE TUMOR NECROSIS FACTOR THERAPY
Baser O1, Wang L2, Xie L1, Yuce H3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Dallas, TX, USA, 3New York City College of Technology-CUNY/STATinMED Research, New York,
NY, USA
OBJECTIVES:Outcomes researchmethodologies need to advance and allow access
by various disciplines as clinicians, epidemiologists, economists, and statisticians
interact frequently. A data visualization tool can help present complex patterns
more effectively to a diverse audience. METHODS: Patients over 65, with at least
one diagnosis for PsA were selected for this study, using the 100% national Medi-
care data with Part D information. We identified patients who initiated therapy
with tumor necrosis factor (TNF) andnon-TNF treatments. For 2 years after biologic
initiation, the following treatment patterns were examined: switching to another
TNF, switching to a non-TNF, and discontinuation.We created a data visualization
tool using a processing language to show how patient treatment patterns change
after the first and second drug switches. RESULTS:A total of 2921 patients initiated
PsA therapy with a TNF agent. 6.44% of these patients switched to another TNF,
2.43% switched to a non-TNF, 51.11% discontinued therapy and 40.02% continued
their initial therapy. Among patients who switched to another TNF, 50.53% re-
mained on the switched therapy, 30.85% discontinued therapy, 18.09% switched to
another TNF, and 0.53% switched to a non-TNF. In 2 years after TNF initiation,
11.76% of patientsmade a second switch from their initial TNF to a third TNFwhile
64.71% continued their second switched drug, 23.53% discontinued the second
switched TNF and no patients switched to a non-TNF. CONCLUSIONS: It can be
difficult to present treatment patterns, especially when analyzing subsequent
years and switches. Data visualization tools can help present these complicated
flows effectively to a diverse health outcomes research audience.
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TREATMENT PATTERN VISUALIZATION OF MEDICARE PATIENTS DIAGNOSED
WITH RHEUMATOID ARTHRITIS AND INITIATING TUMOR NECROSIS FACTOR
THERAPY
Baser O1, Wang L2, Xie L1, Yuce H3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Dallas, TX, USA, 3New York City College of Technology-CUNY/STATinMED Research, New York,
NY, USA
OBJECTIVES: In recent years, methodologies used in outcomes research have ad-
vanced. In a field where different disciplines interact frequently, a tool to commu-
nicate information clearly and effectively through graphical means has become a
necessity. Using data visualization techniques, we present treatment patterns of
patients diagnosed with rheumatoid arthritis (RA).METHODS: Using the 100% na-
tional Medicare data with Part D information, patients who are over age 65 and
have had 2 diagnoses for RA at least 60 days apart were selected for the study. We
identified patients who initiated therapy with tumor necrosis factor (TNF) agents.
For 2 years after the initiation of TNF, we examined treatment patterns such as
switching to another TNF, switching to a non-TNF, and drug discontinuation. Using
a processing language, we created a data visualization tool to illustrate changes in
treatment patterns after first, second and the third switches. RESULTS: A total of
50,455 RA patients initiated therapywith a TNF. 4.37% of these patients switched to
another TNF, 5.81% switched to a non-TNF, 61.52% discontinued therapy and
28.31% continued their initial therapy. Among patients who switched to another
TNF, 37.36% remained on the switched therapy, 46.71% discontinued, 8.40%
switched to another TNF, and 7.54% switched to a non-TNF. In 2 years after TNF
initiation, 7.03% of patients who switched twice after the initial TNF switched a
third time to another TNF, while 51.35% continued their second switched drug,
35.68% discontinued their second switched TNF, and 5.95% switched to a non-TNF.
CONCLUSIONS: Treatment patterns can be difficult to present, especially if they
were analyzed for subsequent years and switches. Data visualization tools can
assist researchers in the effective presentation of these complicated flows.
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DEPRESSION TREATMENT PATTERNS AMONG INDIVIDUALS WITH ARTHRITIS
Agarwal P, Pan XL, Sambamoorthi U
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To examine the patterns of depression treatment among individuals
with arthritis and depression by demographic, socioeconomic, access to care,
health status and lifestyle risk factors. METHODS: We used a cross-sectional de-
sign. Our data source was the 2008 annual release of Medical Expenditures Panel
Survey (MEPS). Individuals with self-reported arthritis were identified from medi-
cal conditions andhousehold files. Presence of depressionwas captured frommed-
ical conditions file. The study sample consisted of 947 adults with arthritis and
depression. Unadjusted group differences in depression treatment patterns among
individuals with arthritis and depression were analyzed using Chi-square tests.
Multinomial logistic regressions were used to examine the relationship between
depression treatment and demographic, socioeconomic, access to care, health sta-
tus and lifestyle risk factors. All analysis accounted for complex survey design of
MEPS. RESULTS: Overall, 20% of individuals with arthritis and depression had no
depression treatment, 56%used antidepressants only and 24%used psychotherapy
with or without antidepressants. After controlling for all other independent vari-
ables, we found that compared to whites, African Americans (AOR0.37) and Lati-
nos (AOR0.28) were significantly less likely to use antidepressants only. Individ-
uals with middle income (AOR0.32) were significantly less likely to receive
psychotherapy with or without antidepressants, than individuals with high
income. CONCLUSIONS: One in every five individuals with both arthritis and de-
pression did not have any treatment for depression. Racial and socio-economic
disparities in depression treatment were found. Further research is required to
explore that whether lack of depression treatment results in poor health outcomes
related to arthritis among individuals with arthritis and depression.
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ESTIMATING INCIDENCE AND PREVALENCE OF OSTEOARTHRITIS (OA) IN
ALBERTA USING ADMINISTRATIVE CLAIMS DATA
Marshall D1, Enns E2, Vanderby S3, Frank C2, Maxwell C1, Wasylak T4, Mosher DP1,
Barnabe C1, Noseworthy T1
1University of Calgary, Calgary, AB, Canada, 2Alberta Bone & Joint Health Institute, Calgary, AB,
Canada, 3University of Saskatchewan, Saskatoon, SK, Canada, 4Alberta Health Services,
Calgary, AB, Canada
OBJECTIVES: OA is a highly prevalent disease with significant economic implica-
tions. With increased aging and obesity, the incidence and prevalence of OA is
expected to continually rise, resulting in higher utilization of health resources. As
part of a systems dynamicmodelling research programme to inform OA care plan-
ning in Alberta, we used provincial administrative data to estimate OA prevalence
and incidence and examined the sensitivity of estimates to different OA case
definitions.METHODS:WeobtainedAlberta Health andWellness (AHW)Discharge
Abstract (DAD), Physician Claims (Claims) and Ambulatory Care Classification Sys-
tem (ACCS) databases from 1994 to 2010with ICD-9 and ICD-10 OA diagnosis codes
(715 and M15-19 codes) identified in any field. In the base case, OA incidence and
prevalence was captured for patients documented with this diagnosis who had at
least two physician OA visits within two years. RESULTS: The incidence and prev-
alence of OA in 2008were estimated at 7.5 cases/1000 population and 87 cases/1000
population, respectively. OA prevalence wasmost affected by run-in time (number
of years of data), followed by the number of physician visits used to define OA, the
number of years between cases, and the databases applied in the analysis. Over 15
years, prevalence approaches steady-state. Physician Claims data captured most
(98%) of the OA cases.CONCLUSIONS:Administrative data have limitations but are
the only routinely collected population level source for these estimates. The key
factors that impact incidence and prevalence estimates for chronic diseases, like
OA, is the number of years of historical data and number of visits used in the case
definition. These estimates most likely underestimate OA prevalence, but likely
capture clinically relevant disease for which patients seek care. The value of these
data for health authorities is to allow for better prediction of demand for planning
future health services.
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